Viracta Therapeutics (VIRX)

Executive Summary

Viracta Therapeutics was a clinical-stage biotechnology company focused on developing therapies for virus-associated malignancies, particularly Epstein-Barr virus (EBV)-positive cancers. The company's proprietary platform aimed to selectively induce viral replication in tumor cells and exploit that activity for targeted cytotoxicity. Despite advancing multiple clinical trials, including a Phase 2 study for EBV-associated lymphoma and a Phase 1/2 for nasopharyngeal carcinoma, Viracta ceased operations in 2024. All trials were terminated by early 2025. The company's dissolution was driven by financial challenges and lack of momentum in the highly competitive oncology landscape. As of 2026, Viracta no longer conducts business, and its assets, if any, are likely in the process of liquidation.